Camila Coelho, PhD, MBA, Named Rising Star by Union of Immunological Societies
Mount Sinai faculty earns an esteemed prize for early-stage researchers who are revolutionizing the field
The International Union of Immunological Societies (IUIS) has named Camila Coelho, PhD, MBA, Assistant Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, as one of its 2025 IUIS Rising Stars. The IUIS Early Career Committee bestows this esteemed prize to early-stage researchers who are revolutionizing immunology through high-impact, creative research.
Within Mount Sinai’s Center for Vaccine Research and Pandemic Preparedness, Dr. Coelho is the head of the Coelho Lab, where she and her team study human B cell responses to infections and vaccines against emerging pathogens. Her aim is to acquire a better understanding of the immunological processes that underlie defense against newly developing viral illnesses such as Mpox, by combining experimental and bioinformatics methods.
"Dr. Coelho is a pioneering immunologist whose work at the intersection of human immunology, computational biology, and vaccines is significantly improving global health," said Ana Fernandez-Sesma, PhD, Chair of the Department of Microbiology at the Icahn School of Medicine. "The IUIS's designation of her as a 2025 Rising Star is evidence of her scientific vision and dedication to the advancement of translational immunology."
Dr. Coelho was involved in groundbreaking research in human vaccine immunology before joining Mount Sinai, and she is still studying how antibody responses and B cell memory change after vaccination and illness. Her research directly affects the development of next-generation vaccination plans and the effectiveness of vaccines.
Dr. Coelho began her studies in Brazil and her postdoctoral trainings were carried out at the La Jolla Institute for Immunology, the National Institute of Allergy and Infectious Diseases and Georgetown University.
Dr. Coelho is one of just a few early-career scientists worldwide who have been honored by the IUIS for advancing immunology research and exhibiting leadership potential in the field. Go to www.coelholab.com to find out more about the studies conducted by the Coelho lab.
Visit https://iuis.org/news/meet-the-iuis-2025-rising-stars for additional details about the IUIS Rising Stars program and the entire 2025 cohort.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.